Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Non-Current Liabilities: 2024-2025

Historic Total Non-Current Liabilities for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Sep 2025 value amounting to $62.2 million.

  • Day One Biopharmaceuticals' Total Non-Current Liabilities was N/A to $62.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.2 million, marking a year-over-year change of. This contributed to the annual value of $79.3 million for FY2024, which is N/A change from last year.
  • Day One Biopharmaceuticals' Total Non-Current Liabilities amounted to $62.2 million in Q3 2025, which was up 8.20% from $57.4 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $79.3 million during Q4 2024, with a 5-year trough of $54.1 million in Q1 2025.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $59.8 million (2025), whereas its average is $63.2 million.